Chantix No Riskier Than Nicotine Patch, Gum: Studies

Law360, New York (October 24, 2011, 7:15 PM EDT) -- Two government-sponsored studies have found that patients using nicotine patches, nicotine gum or other nicotine replacement products were as likely as those taking Pfizer Inc.'s smoking cessation drug Chantix to be hospitalized for psychiatric problems, federal regulators said Monday.

While the U.S. Food and Drug Administration has acknowledged the results of the studies, it continues to require a boxed warning that Chantix could cause suicidal thoughts, depression, hostility and agitation.

The agency cautioned that the studies did not have a large enough sample size to detect...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.